Kristleifur Kristjansson
Plus aucun poste en cours
Profil
Kristleifur Kristjansson was the founder of deCODE genetics, Inc. where he held the title of Vice President-Clinical Affairs from 1995 to 2012.
He is also the founder of Skraeda ehf.
Kristleifur's former job was as the Executive Vice President-Research & Development at Össur hf from 2012 to 2022.
Dr. Kristjansson earned a doctorate degree from the University of Iceland.
Anciens postes connus de Kristleifur Kristjansson
| Sociétés | Poste | Fin |
|---|---|---|
| EMBLA MEDICAL HF. | Chief Tech/Sci/R&D Officer | 01/07/2022 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Founder | 01/01/2012 |
| Skraeda ehf | Founder | - |
Formation de Kristleifur Kristjansson
| University of Iceland | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EMBLA MEDICAL HF. | Health Technology |
| Entreprise privées | 2 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
| Skraeda ehf |
